middle.news
How Will Avecho’s Phase III CBD Trial and Sandoz Deal Shape Its Future?
6:04pm on Friday 27th of February, 2026 AEDT
•
Biotechnology
Read Story
How Will Avecho’s Phase III CBD Trial and Sandoz Deal Shape Its Future?
6:04pm on Friday 27th of February, 2026 AEDT
Key Points
Revenue up 9.3% to $1.24 million
Net loss increased 41.5% to $4.42 million
Phase III CBD insomnia trial nearing interim analysis with 190 of 210 patients dosed
Exclusive Australian licensing deal with Sandoz includes $4.8 million upfront and potential $16 million milestones
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
AVECHO BIOTECHNOLOGY (ASX:AVE)
OPEN ARTICLE